Acurx Pharmaceuticals, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

ISSUANCE OF EQUITY INTERESTS (Details)

ISSUANCE OF EQUITY INTERESTS (Details) - USD ($)							1 Months Ended			3 Months Ended
ISSUANCE OF EQUITY INTERESTS (Details) - USD ($)	Mar. 06, 2025	Jan. 06, 2025	Nov. 15, 2023	May 18, 2023	Jul. 27, 2022	Jun. 29, 2021	Mar. 31, 2025	Jan. 31, 2025	Jan. 31, 2024	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Jun. 23, 2021
Equity
Common stock, Authorized (in shares)							200,000,000			200,000,000		200,000,000	200,000,000
Common stock, Outstanding (in shares)							22,397,511			22,397,511		17,030,686
Common stock, Issued (in shares)							22,397,511			22,397,511		17,030,686
Shares issued (in shares)				601,851	1,159,211	2,875,000
Common stock par value (in dollars per share)							$ 0.001			$ 0.001		$ 0.001
Share sales price (in dollars per share)						$ 6
Warrants exercised (in shares)										595,000
Proceeds from warrant exercises											$ 210,199
Proceeds from stock issue				$ 4,000,000	$ 4,200,000	$ 17,300,000
Series A warrants
Equity
Number of warrants					1,289,980
Series B warrants
Equity
Number of warrants					1,289,980
Series C warrants
Equity
Number of warrants				1,333,333
Series D warrants
Equity
Number of warrants				1,333,333
Series F warrants
Equity
Warrants term	24 months
Affiliate Investors \| Series B warrants
Equity
Warrants exercised (in shares)									59,211
Proceeds from warrant exercises									$ 200,000
Underwriter option
Equity
Number of warrants	164,700
Warrant exercise price (in dollars per share)	$ 0.5
Warrants term	24 months
Underwriter option \| Series E warrants
Equity
Number of warrants		147,783
Warrant exercise price (in dollars per share)		$ 1.2688
January 2025 Registered Direct Offering [Member]
Equity
Shares issued (in shares)		2,463,058
Common stock par value (in dollars per share)		$ 0.001
Share sales price (in dollars per share)		1.015
Warrant exercise price (in dollars per share)		$ 0.9
Warrants term		5 years
Proceeds from stock issue		$ 2,500,000						$ 2,100,000
Net proceeds stock issuance		$ 2,100,000								$ 2,099,253
Registered Direct Offering costs										85,419
January 2025 Registered Direct Offering [Member] \| Series E warrants
Equity
Number of warrants		2,463,058
January 2025 Registered Direct Offering [Member] \| Affiliate Investors
Equity
Shares issued (in shares)		167,488
January 2025 Registered Direct Offering [Member] \| Affiliate Investors \| Series E warrants
Equity
Number of warrants		167,488
January 2025 Registered Direct Offering [Member] \| Investor
Equity
Shares issued (in shares)		2,295,570
January 2025 Registered Direct Offering [Member] \| Investor \| Series E warrants
Equity
Number of warrants		2,295,570
March 2025 Registered Direct Offering [Member]
Equity
Shares issued (in shares)	2,150,000
Common stock par value (in dollars per share)	$ 0.001
Share sales price (in dollars per share)	$ 0.4
Number of warrants	595,000
Warrant exercise price (in dollars per share)	$ 0.3999
Proceeds from stock issue	$ 1,100,000						$ 900,000
Net proceeds stock issuance	$ 900,000									889,420
Registered Direct Offering costs										$ 56,163
March 2025 Registered Direct Offering [Member] \| Series F warrants
Equity
Number of warrants	8,235,000
Warrant exercise price (in dollars per share)	$ 0.4
At the Market Offering
Equity
Shares issued (in shares)											1,121,793
Share sales price (in dollars per share)											$ 3.95
Proceeds from stock issue											$ 4,400,000
Net proceeds stock issuance											$ 4,299,474
Aggregate offering price			$ 17,000,000